These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17554594)

  • 1. Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain.
    Atiemo AD; Ng'Alla LS; Vaidya D; Williams MS
    J Thromb Thrombolysis; 2008 Apr; 25(2):173-8. PubMed ID: 17554594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays.
    Can MM; Tanboğa IH; Türkyilmaz E; Karabay CY; Akgun T; Koca F; Tokgoz HC; Keles N; Ozkan A; Bezgin T; Ozveren O; Sonmez K; Sağlam M; Ozdemir N; Kaymaz C
    Thromb Res; 2010 Apr; 125(4):e132-7. PubMed ID: 19954823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
    Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
    Christie DJ; Kottke-Marchant K; Gorman RT
    Platelets; 2008 Mar; 19(2):104-10. PubMed ID: 17852773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study.
    Tobin WO; Kinsella JA; Collins DR; Coughlan T; O'Neill D; Egan B; Tierney S; Feeley TM; Murphy RP; McCabe DJ
    Br J Haematol; 2011 Mar; 152(5):640-7. PubMed ID: 21223254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
    Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
    Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring aspirin treatment in patients with thrombocytosis: comparison of the platelet function analyzer (PFA)-100 with optical aggregometry.
    Tsantes AE; Mantzios G; Giannopoulou V; Tsirigotis P; Bonovas S; Rapti E; Mygiaki E; Kartasis Z; Sitaras NM; Dervenoulas J; Travlou A
    Thromb Res; 2008; 123(1):100-7. PubMed ID: 18430462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients.
    Lepäntalo A; Mikkelsson J; Reséndiz JC; Viiri L; Backman JT; Kankuri E; Karhunen PJ; Lassila R
    Thromb Haemost; 2006 Feb; 95(2):253-9. PubMed ID: 16493486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet hyper-function in acute coronary syndromes.
    Harrison P; Mackie I; Mathur A; Robinson MS; Hong Y; Erusalimsky JD; Machin SJ; Martin JF
    Blood Coagul Fibrinolysis; 2005 Nov; 16(8):557-62. PubMed ID: 16269928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors responsible for "aspirin resistance" - can we identify them?
    Postuła M; Tarchalska-Kryńska B; Filipiak KJ; Kosior D; Serafin A; Huczek Z; Opolski G
    Kardiol Pol; 2010 Apr; 68(4):403-11; discussion 412-3. PubMed ID: 20425699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin.
    Takahashi S; Ushida M; Komine R; Shimizu A; Uchida T; Ishihara H; Shibano T; Watanabe G; Ikeda Y; Murata M
    Thromb Res; 2007; 119(4):517-24. PubMed ID: 16793119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study.
    Tobin WO; Kinsella JA; Coughlan T; Collins DR; O'Neill D; Murphy RP; Egan B; Tierney S; Feeley TM; McCabe DJ
    Eur J Neurol; 2013 Feb; 20(2):344-52. PubMed ID: 22994699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.
    Kojuri J; Mahmoody Y; Zangbar Sabegh B; Jannati M; Mahboodi A; Khalili A
    Cardiovasc Ther; 2010 Jun; 28(3):147-52. PubMed ID: 20557313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
    Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
    Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.
    Salama MM; Morad AR; Saleh MA; Sabri NA; Zaki MM; ElSafady LA
    J Clin Pharm Ther; 2012 Dec; 37(6):630-6. PubMed ID: 23121257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using the Platelet Function Analyzer-100 for monitoring aspirin therapy.
    Poulsen TS; Mickley H; Korsholm L; Licht PB; Haghfelt T; Jørgensen B
    Thromb Res; 2007; 120(2):161-72. PubMed ID: 17052745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.
    Christiaens L; Ragot S; Mergy J; Allal J; Macchi L
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):235-9. PubMed ID: 18388505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.
    Reny JL; De Moerloose P; Dauzat M; Fontana P
    J Thromb Haemost; 2008 Mar; 6(3):444-50. PubMed ID: 18194417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.